Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Clinical trial NCT04187898 · COMPLETED
Trial details
- NCT number
- NCT04187898
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-11
- Primary completion
- 2024-07-16
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.